Avalo Therapeutics
Stock Forecast, Prediction & Price Target
Avalo Therapeutics Financial Estimates
Avalo Therapeutics Revenue Estimates
Avalo Therapeutics EBITDA Estimates
Avalo Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $5.39M N/A | $18.05M 234.40% | $1.92M -89.34% | Avg: $1M Low: $1M High: $1M avg. -48.02% | Avg: $1M Low: $1M High: $1M avg. 0% | Avg: $1M Low: $1M High: $1M avg. 0% | Avg: $1.70M Low: $1.70M High: $1.70M avg. 70.57% |
Net Income
% change YoY
| $-84.34M N/A | $-41.65M 50.61% | $-31.54M 24.27% | Avg: $-36M Low: $-269.39K High: $-269.39K avg. -14.12% | Avg: $-39M Low: $-286.05K High: $-286.05K avg. -8.33% | Avg: $-313.83K Low: $-313.83K High: $-313.83K avg. 99.19% | Avg: $-341.60K Low: $-341.60K High: $-341.60K avg. -8.84% |
EBITDA
% change YoY
| $-80.58M N/A | $-37.42M 53.56% | $-27.95M 25.29% | Avg: $-1M Low: $-1M High: $-1M avg. 96.42% | Avg: $-1M Low: $-1M High: $-1M avg. 0% | Avg: $-1M Low: $-1M High: $-1M avg. 0% | Avg: $-1.70M Low: $-1.70M High: $-1.70M avg. -70.57% |
EPS
% change YoY
| -$2,330.66 N/A | -$1,062.65 54.40% | -$113.58 89.31% | Avg: -$0.97 Low: -$0.97 High: -$0.97 avg. 99.14% | Avg: -$1.03 Low: -$1.03 High: -$1.03 avg. -6.18% | Avg: -$1.13 Low: -$1.13 High: -$1.13 avg. -9.70% | Avg: -$1.23 Low: -$1.23 High: -$1.23 avg. -8.84% |
Operating Expenses
% change YoY
| $86.04M N/A | $52.05M -39.49% | $640K -98.77% | Avg: $3.14M Low: $3.14M High: $3.14M avg. 391.81% | Avg: $3.14M Low: $3.14M High: $3.14M avg. 0% | Avg: $3.14M Low: $3.14M High: $3.14M avg. 0% | Avg: $5.36M Low: $5.36M High: $5.36M avg. 70.57% |
FAQ
What is Avalo Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 16.97% in 2025-2028.
We have gathered data from 1 analysts. Their low estimate is -269.39K, average is -36M and high is -269.39K.
What is Avalo Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 5.63% in 2025-2028.
We have gathered data from 1 analysts. Their low revenue estimate is $1M, average is $1M and high is $1M.
What is Avalo Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 18.60% in 2025-2028.
We have gathered data from 1 analysts. Their low earnings per share estimate is -$0.97, average is -$0.97 and high is $-0.97.
What is the best performing analyst?
In the last twelve months analysts have been covering Avalo Therapeutics stock. The most successful analyst is Leland Gershell.